The clinical relevance of dry powder inhaler performance for drug delivery  by Demoly, Pascal et al.
Respiratory Medicine (2014) 108, 1195e1203Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate/rmedThe clinical relevance of dry powder inhaler
performance for drug delivery
Pascal Demoly a,*, Paul Hagedoorn b, Anne H. de Boer b,
Henderik W. Frijlink ba De´partement de Pneumologie et Addictologie, Hoˆpital Arnaud de Villeneuve and University Hospital
of Montpellier, 371 Ave. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
b Department of Pharmaceutical Technology and Biopharmacy, University of Groningen,
Ant. Deusinglaan 1, 9713 AV Groningen, The NetherlandsReceived 29 January 2014; accepted 13 May 2014
Available online 24 May 2014KEYWORDS
Fine particle fraction;
Inhaler resistance;
Lung deposition;
Dry powder inhaler* Corresponding author. Tel.: þ33 46
E-mail address: pascal.demoly@ins
http://dx.doi.org/10.1016/j.rmed.201
0954-6111/ª 2014 Published by ElseviSummary
Background: Although understanding of the scientific basis of aerosol therapy with dry powder
inhalers (DPIs) has increased, some misconceptions still persist. These include the beliefs that
high resistance inhalers are unsuitable for some patients, that extra fine (<1.0 mm) particles
improve peripheral lung deposition and that inhalers with flow rate-independent fine particle
fractions (FPFs) produce a more consistent delivered dose to the lungs.
Objectives: This article aims to clarify the complex inter-relationships between inhaler design
and resistance, inspiratory flow rate (IFR), FPF, lung deposition and clinical outcomes, as a bet-
ter understanding may result in a better choice of DPI for individual patients.
Methods: The various factors that determine the delivery of drug particles into the lungs are
reviewed. These include aerodynamic particle size distribution, the inspiratory manoeuvre,
airway geometry and the three basic principles that determine the site and extent of deposi-
tion: inertial impaction, sedimentation and diffusion. DPIs are classed as either dependent or
independent of inspiratory flow rate and vary in their internal resistance to inspiration. The
effects of these characteristics on drug deposition in the airways are described using data from
studies directly comparing currently available inhaler devices.
Results: Clinical experience shows that most patients can use a high resistance DPI effectively,
even during exacerbations. Particles in the aerodynamic size range from 1.5e5 mm are shown
to be optimal, as particles <1.0 mm are very likely to be exhaled again while those >5 mm may
impact on the oropharynx. For DPIs with a constant FPF at all flow rates, less of the delivered
dose reaches the central and peripheral lung when the flow rate increases, risking under-
dosing of the required medication. In contrast, flow rate-dependent inhalers increase their
FPF output at higher flow rates, which compensates for the greater impaction on the upper
airways as flow rate increases.7336117; fax: þ33 467042708.
erm.fr (P. Demoly).
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1196 P. Demoly et al.Conclusions: The technical characteristics of different inhalers and the delivery and deposition
of the fine particle dose to the lungs may be important additional considerations to help the
physician to select the most appropriate device for the individual patient to optimise their
treatment.
ª 2014 Published by Elsevier Ltd.Introduction
The mainstay of asthma and COPD treatment is via the
inhaled route, medication given either to control inflam-
mation (inhaled corticosteroids [ICS]) or to prevent or
reverse bronchoconstriction (b2-agonist or muscarinic
antagonist bronchodilators) [1]. A key advantage of the
inhaled route of administration is that lower doses of the
required drug can be delivered directly to the site of ac-
tion, resulting in a rapid clinical response with lower po-
tential for risk of systemic adverse effects compared with
other routes of administration [2,3].
Increased understanding of the scientific basis of aerosol
therapy has led to the development and introduction of
many new inhaler devices, including nebulisers, pressurised
metered-dose inhalers (pMDIs) and, particularly, dry pow-
der inhalers (DPIs) [3e5]. Approaches including Adaptive
Aerosol Delivery (AAD) [6], the AKITA inhalation system
(Activaero, Germany), which controls the breathing
manoeuvre [7] and mist inhalers [8], have utilised and
exploited new insights into the relationships between fac-
tors such as delivered dose, aerosol particle size, inspira-
tory flow rate (IFR), lung deposition and clinical effects.
These insights have also led to a greater awareness of the
importance of choice of DPI to suit the individual patient.
Despite these advances in scientific understanding, a
number of misconceptions about inhalers have proved very
persistent. These include the belief that the optimal flow
rate or pressure drop to operate a DPI is 60 L/min or 4 kPa,
irrespective of the inhaler design. Other misconceptions
include the role of the inhaler’s internal resistance, the
belief that extra fine particles (with mass median aero-
dynamic diameter [MMAD] <1 mm) give improved peripheral
lung deposition and the belief that inhalers with flow rate
independent particle size distribution produce a more
consistent delivered dose to the lungs. However, it is
beginning to become more widely understood that there is
no unique IFR nor pressure drop for optimal use of DPIs. It
has also become accepted that higher resistance DPIs can
be used effectively, both by COPD patients and by children
with an asthma exacerbation, and that they can have
several advantages with respect to lung deposition [9e13].
Furthermore, there are good theoretical arguments (with
experimental support) to question the benefit of extra fine
(<1 mm) particles and flow rate independent aerosol de-
livery [14]. And finally, lung deposition is not always
improved by inhaling faster or more forcefully [15].
Despite the many recent advances and innovations,
inhalation therapy is also still associated with poor adher-
ence and many patients have low levels of ability/dexterity
or poor breath-to-hand co-ordination and so use theirinhaler device incorrectly/ineffectively [16,17]. Even with
training, there is a high potential for handling errors,
particularly when patients are prescribed different types of
inhaler concurrently [18]. Patients also develop strong
preferences for specific types of inhalers [19e23], which
can have an impact on adherence, particularly if they are
switched to a different inhaler type [24]. Switching inhaler
device, particularly if the decision is made without
consultation, is not recommended [25]. Care should also be
taken even when switching among the same type of inhaler
e for example a DPI e because different levels of asthma
control are achieved even when delivering the same drug
[26].
In an effort to reduce the impact of inevitable handling
errors, research has been done to produce inhalers that are
less dependent on the user for delivery of the optimum
dose [27]. In this regard, the performance and specific
design characteristics of a DPI, such as the delivered par-
ticle size distribution and their internal resistance, have
been shown to be important from a clinical perspective, in
that they can be modified to minimise the influence of the
patient’s IFR on the deposition pattern and dose [3,4,16].
The aerosol particle size distribution is known to be one
of the main factors influencing the deposition pattern of a
drug in the lungs. Historically, the optimal aerodynamic
particle size range for deposition in the lung was thought to
be <5 mm. The mass fraction of the dose emitted in this size
range by a particular inhaler is often referred to as the fine
particle fraction (FPF) [28]. The factors determining the
FPF generated by a DPI are complex and interrelated [29].
The aims of this article are to clarify the complex
interplay between inhaler design and resistance, inspira-
tory flow manoeuvre, FPF and lung deposition, and to
highlight the clinical relevance of this interplay, in terms of
effectiveness and outcomes.
Particle size matters
Aerodynamic particle size distribution, in combination with
the inspiratory manoeuvre and airway geometry, de-
termines the penetration of drug particles into the airways
and deposition on the walls of the airways e and this de-
termines the dose delivered to the target site
[13,16,30e33]. Three basic principles are the main de-
terminants of the site and extent of deposition e inertial
impaction, sedimentation and (to a lesser extent) diffusion
(Fig. 1) [29,30,34]. Particles that are not deposited are
exhaled again.
At higher IFRs, most particles >5 mm in diameter will
impact on the oropharynx and in the first airway bifurca-
tion. Particles deposited on the oropharynx will be
Figure 1 Dominant particle deposition mechanisms in the respiratory tract and effect of particle size on the likelihood of particle
penetration and deposition in the airways.
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cacy and local oropharyngeal or systemic effects. This was
demonstrated by Usmani and colleagues in a randomised,
double-blind, placebo-controlled clinical efficacy study in
12 patients with stable mild-to-moderate asthma quanti-
fying deposition with salbutamol aerosols of different par-
ticle size (either 1.5, 3 or 6 mm MMAD) at two different flow
rates (31 or 67 L/min) [35]. The study demonstrated that
deposition fractions of smaller particles (1.5 and 3 mm) in
the central and peripheral airways are much higher than
those of larger (6 mm) particles, particularly at the higher
IFR (Fig. 2) [35]. By extrapolation of data from this study, it
can be derived that particles of 1 mm have a greater than
40% chance of being exhaled again (both flow rates) due to
their low settling velocity, in spite of a short breath-hold
period. Bronchodilation (measured as change in forced
expiratory volume in 1 s [FEV1]) following administration of
salbutamol significantly decreased with particle size at the
higher IFR [35]. Bronchodilation with the 1.5 mm particles
was unaffected by IFR. Oropharyngeal deposition increasedFigure 2 Effect of different inspiratory flow rates (31 or
67 L/min) on lung deposition for three different sizes of par-
ticle (1.5, 3.0 or 6.0 mm). Adapted from Usmani et al. (2005)
[35].for all particle sizes at the higher IFR, but this was signifi-
cantly greater for the larger particles (p < 0.001). These
findings highlight the dynamic interaction between FPF and
IFR and show that this translates into clinical outcomes, i.e.
decreased lung deposition and increased oropharyngeal
deposition with the higher IFR for large particle sizes results
in a reduced bronchodilator effect (Fig. 3) [35]. The Usmani
study used monodisperse aerosols (geometric standard de-
viation <1.22) and similar effects may be expected for
aerosols from DPIs with the same MMAD, although they may
have slightly wider size distributions.
Although, historically, the optimal aerodynamic particle
size range for deposition in the lung was thought to be
<5 mm, basic physics, deposition modelling and also in vivo
deposition studies (e.g. Usmani et al. [35]) indicate that
particles smaller than 1.0 mm are undesirable because of
their extremely low settling velocity [29]. Because the
settling velocity increases with the square of the particleFigure 3 Clinical effects of relationship between inspiratory
flow rate (slow [31 L/min] and fast [67 L/min]) and particle size
for monodisperse salbutamol aerosols in 12 patients with stable
mild-to-moderate asthma [35]. FEV1, forced expiratory volume
in 1 s; ns, not significant.
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increases rapidly when the particle diameter is increased.
For 1.5 mm particles, the time to travel the same distance
by falling is 2.25 times shorter than that for 1 mm particles.
Also, the chance of inertial deposition in the larger airways
increases with increasing diameter, but for particles of
approximately 1.5 mm, the oropharyngeal deposition is still
low and widely flow rate independent [35]. Therefore,
particles of 1.5 mm are more appropriate than <1.0 mm
particles and the optimal size range for inhalation seems to
be 1.5e5 mm rather than <5 mm.Figure 4 (A) FPF <5 mm by pressure drop across different
inhalers and (B) flow rates of various inhalers at which the FPF
<5 mm reaches 25% of the label claim. FPF, fine particle
fraction.Drug distribution and concentration in the
whole lung
For aerosols from DPIs a reasonably equal distribution
(1:1:1) of the total lung dose has been found between the
upper (conducting), intermediate (transitional) and lower
(peripheral) airways [33,36]. Usmani et al. reported com-
parable lung distributions for 1.5e3 mm particles inhaled at
30e67 L/min: about two-thirds of total lung dose was
deposited in the central plus intermediate and one-third in
the peripheral airways (Fig. 2) [35]. This seems to be in fair
agreement with the lung distribution from DPIs, although
the definitions for central, intermediate and peripheral
lung may have been different. However, due to the expo-
nential increase in airway surface area towards the alveoli,
so that over 95% of lung surface area is within peripheral
airways, the actual concentration for a given dose of drug is
significantly higher in the conducting airways than the
respiratory airways [33,37]. Differences in average con-
centration between the conducting and peripheral airways
for a 1:1:1 deposition ratio may approach a factor of 100.
Deviations from the 1:1:1 ratio in the deposition pattern do
not really level out this extreme concentration difference.
Even for a ratio of 1:2:3 in favour of a much higher pe-
ripheral deposition, which is difficult to achieve in practice
with pMDIs and DPIs, the average concentration difference
between conducting and peripheral airways is still a factor
>30. At the clinical level, this may be highly relevant for
drugs that need to particularly target the smaller airways,
like corticosteroids, or that need to be more evenly
distributed over the entire lung, like antibiotics. Only for
bronchodilators has this concentration gradient been
considered less relevant so far. Although b2-agonists and
anticholinergics target autonomic receptors on the airway
smooth muscle of large and small airways [38], cholinergic
activity of the lung is most pronounced in the large airways
[39]. Additionally, the amount of smooth muscle gradually
decreases from the bronchioles towards the alveoli.
Therefore, targeting the larger airways with bronchodila-
tors has been the objective until now. However, several
studies are currently underway to investigate the contri-
bution of small airways to asthma and COPD. Recently, it
has been proposed that muscarinic receptors may have a
much greater role in the pathophysiology of obstructive
airway diseases than previously thought [40]. Drugs like
tiotropium may potentially inhibit airway inflammation and
remodelling [41], whereas for aclidinium an important role
in inhibiting fibroblastemyofibroblast transition has been
reported, which is a key step in peribronchiolar fibrosisformation [42]. For these reasons, and also to achieve the
desired synergistic effect with ICS, achieving high drug
concentrations in the central and peripheral lung may
become a future challenge for anticholinergic bronchodi-
lators too. However, a balance must be achieved on parti-
cle size, because any drug capable of reaching the alveoli is
more likely to be absorbed into the circulation and increase
the potential for adverse systemic effects [29].
Flow rate: dependence or independence?
DPIs fall into two main classes e according to whether their
FPF output is dependent on, or independent of, the user’s
IFR [13,16,29,30]. Fig. 4 shows that the percentage of ICS
fine particles <5 mm from the (Pulmicort and Symbicort)
Turbuhaler and the (Budelin) Novolizer inhaler in-
creases at higher IFR, while for the (Seretide) Diskus,
budesonide Cyclohaler and (Rolenium) Elpenhaler, the
percentage is relatively unchanged at different IFRs. It has
to be borne in mind that pharmaceutical companies may
use different definitions for their label claims, which blurs
any performance comparison between devices. Some
companies take the weighed drug amount as reference for
their label claim whereas others base their label claim
instead on the average drug mass released from the
mouthpiece.
Whilst an inhaler that produces a consistent percentage
of FPF <5 mm independent of the IFR of the patient may
appear at first sight to be the best way to ensure repro-
ducible lung deposition, the reality is quite the opposite. An
IFR-dependent inhaler produces an increased FPF <5 mm at
Figure 5 (A) Flow-rate independent inhalers such as Diskus
provide a decreasing dose to the central and peripheral airways
as air flow rates (pressure drops) increase, whereas (B) flow-
rate dependent inhalers such as Novolizer maintain their
lung deposited dose as air flow rates (and pressure drops) in-
crease [29,30,47].
Figure 6 Scanning electron micrographs of (A) adhesive
mixture and (B) soft spherical agglomerates/pellets.
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towards larger airways due to increased inertial impaction
in the oropharynx and first airway bifurcation
[29,30,33,36,43e48], which otherwise reduces deposition
in the peripheral respiratory airways of the lung at higher
IFRs. The compensation should ensure that a relatively
constant dose is delivered to where it is needed in the lung
regardless of IFR. An example of the difference in lung
deposition between constant and IFR-dependent FPF <3 mm
is given in Fig. 5 for a comparison between the Diskus and
Novolizer. Based on the data from an in vitro deposition
study and by making use of deposition probability equations
for particles in the delivered size range, the proportions of
this FPF that are deposited in the upper airways and central
plus peripheral airways, respectively, can be assessed, as a
function of the inspiratory flow rate [30].
IFR-independent inhalers, such as the Diskus, produce
a constant percentage of FPF over a wide range of IFRs,
but, at higher IFRs, significantly reduced amounts of the
constant fine particle dose actually reach the peripheral
airways. The decrease in computed dose reaching the pe-
ripheral airways with this IFR-independent inhaler is from
6.7% to 2.2% (Fig. 5A) [30]. Clinically, this means thatpatients with higher or variable IFRs using IFR-independent
inhalers risk under-dosing, particularly with ICS therapies,
which, unlike the fast-acting bronchodilators, do not give
immediate response feedback to the patient so that they
can tell whether their inhalation was insufficient and
repeat the procedure if necessary [49]. In contrast, with
increasing percentage FPF at higher IFR, the computed
peripheral lung dose from the Novolizer varies from 6.3%
to 10.8% (Fig. 5B). These computed values are in good
agreement with the data from a lung deposition study in
healthy volunteers with radiolabeled budesonide aerosols
from the Novolizer yielding peripheral lung depositions of
6.5% (at 45 L/min), 7.8% (60 L/min) and 8.5% (90 L/min),
respectively [36].
Meeting resistance
Drugs for inhalation by DPI in the treatment of asthma and
COPD therapy are supplied in one of two forms, either as a
so-called adhesive mixture or as soft spherical agglomer-
ates, referred to as pellet formulation (Fig. 6). In adhesive
mixture formulations, the micronised drug particles are
distributed over the surface of coarse carrier particles by
natural adhesion. Pellet formulations may consist of pure
Table 1A Review of some corticosteroid (ICS) delivering DPIs.
Inhaler ICS Manufacturer % FPF at 4 kPa Resistancea FPF as Fu(IFR) Multi-/single-
unit doseDefined as % FPF
Flixotide Diskus FLU GSK <5 mm 20e25 Medium/low Constant Multi-unit
Seretide Diskus FLU GSK <5 mm 20e25 Medium/low Constant Multi-unit
Flixotide Diskhaler FLU GSK <5 mm 25e30 Medium/low Constant Multi-unit
Rolenium Elpenhaler FLU Elpen <5 mm 15e20 Medium/low Constant Single-unit
Pulmicort Turbuhaler BUD AstraZeneca <5 mm 30e35 Medium/high Increasing Multi-unit
Symbicort Turbuhaler BUD AstraZeneca <5 mm 45e50 Medium/high Increasing Multi-unit
Budelin Novolizer BUD Meda <5 mm 40e45 Medium/low Increasing Multi-unit
Budesonide Easyhaler BUD Sandoz <5 mm 20e25 Medium/low Increasing Multi-unit
Budesonide Clickhaler BUD Merck Generics <5 mm 10e15 Medium/high Slightly increasing Multi-unit
Budesonide Cyclohaler BUD Teva Pharma <5 mm 25e30 Low Slightly increasing Single-unit
Budesonide Jethaler BUD Ratiopharm <5.1 mm 35e40 Medium/high Increasing Multi-unit
Foster NEXThaler BDP Chiesi <5 mm 40e45 Medium/high Constant Multi-unit
Asmanex Twisthaler MOM Merck & Co <5 mm 30e35 [51,52] High Slightly increasing Multi-unit
FPF as percent of label claim, unless stated otherwise.
a Defined as: high (IFR at 4 kPa < 45 L/min), medium/high (IFR at 4 kPa between 45 and 60 L/min); medium/low (IFR at 4 kPa between
60 and 80 L/min) and low (IFR at 4 kPa > 80 L/min). BUD, budesonide; BDP, beclomethasone (dipropionate); DPI, dry powder inhaler;
FLU, fluticasone (propionate); FPF, fine particle fraction; ICS, inhaled corticosteroid, IFR, inspiratory flow rate; MOM, mometasone
(furoate).
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micronised excipient. In both examples, the excipient is
usually lactose, which is used to dilute the drug and
improve the flow properties to assist reproducible dosing to
the patient. Adhesive mixtures and pellet formulations
consist initially of particles that are too large to penetrate
to the target area. They have to be de-agglomerated or
dispersed during inhalation to release the drug particles in
the appropriate aerodynamic size range.
The energy for de-agglomeration is derived from the
inhaled air stream. Well-designed inhalers transfer the ki-
netic energy of the airflow effectively into drag, inertial orTable 1B Review of some bronchodilator (BD) delivering DPIs.
Inhaler BD Manufacturer % FPF at 4 kPa
Defined as % F
Serevent Diskus SAL GSK <5 mm 20e
Seretide Diskus SAL GSK <5 mm 20e
Salbutamol Cyclohaler SAL Teva <5 mm 25e
Oxis Turbuhaler FOR AstraZeneca <5.8 mm 35e
Symbicort Turbuhaler FOR AstraZeneca <5 mm 40e
Formatris Novolizer FOR Meda <5 mm 40e
Rolenium Elpenhaler FOR Elpen <5 mm 15e
Foster NEXThaler FOR Chiesi <5 mm 35e
Foradil Aerolizer FOR Merck & Co. <5.8 mm 25e
Onbrez Breezhaler IND Novartis <5 mm 35e
Seebri Breezhaler GB Novartis <5 mm 32e
Eklira Genuair ACC Almirall <5 mm 35e
Spiriva HandiHaler TIO Boehringer I <5 mm 15e
FPF as percent of label claim unless stated otherwise.
a Defined as: high (IFR at 4 kPa < 45 L/min), medium high (IFR at 4 k
60 and 80 L/min) and low (IFR at 4 kPa > 80 L/min). ACC, aclidiniu
formoterol (fumarate dihydrate); FPF, fine particle fraction; GB, glyco
(maleate); SAL, salmeterol (xinafoate); TIO, tiotropium (bromide).frictional forces, which break down the pellet formulations
into primary particles or detach drug particles from the
carrier surface [30]. Optimal utilisation of the kinetic en-
ergy to generate de-agglomeration forces requires design
features that largely determine the inhaler resistance to air
flow. Such features can, for instance, be turbulent shear
zones (creating drag and lift forces) or whirl and circulation
chambers containing impact bodies. Inhalers with highly
effective de-agglomeration principles are more likely to
have a higher air flow resistance and provide greater lung
deposition than those with a low internal resistance
[16,37,50].Resistancea FPF as Fu(IFR) Multi-/single-
unit dosePF
25 Medium/low Slightly increasing Multi-unit
25 Medium/low Constant Multi-unit
30 Low Increasing Single-unit
40 Medium/high Increasing Multi-unit
45 Medium/high Increasing Multi-unit
45 Medium/low Increasing Multi-unit
20 Medium/low Constant Single-unit
40 Medium/high Constant Multi-unit
30 [53] Low Increasing Single-unit
40 Low Constant Single-unit
52 [54] Low Constant Single-unit
40 Medium/low Slightly increasing Multi-unit
20 High Constant Single-unit
Pa between 45 and 60 L/min); medium low (IFR at 4 kPa between
m (bromide); BD, bronchodilator; DPI, dry powder inhaler; FOR,
pyrronium (bromide); IFR, inspiratory flow rate; IND: indacaterol
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for de-agglomeration results in an increasing FPF with
increasing IFR. The clinical relevance of the internal resis-
tance of an inhaler refers not only to a higher proportion of
FPF dose achieved at the same inspiratory effort and a
compensating increase in FPF at higher IFR. Resistance also
has an impact on the site of deposition of drug particles in
the respiratory tract. High-resistance inhalers reduce the
maximal attainable flow rate, which equals the quotient of
the square root of the pressure drop achieved (given in
OkPa) and the inhaler resistance (in kPa0.5 min L1), thus
reducing oropharyngeal deposition. Inhaling against a high
resistance furthermore opens up the oropharynx and vocal
cords, providing a wider passageway for the aerosol and
increasing total lung dose [37].
Most inhalers deliver FPFs between 20% and 30% of the
label claim at pressure drops between 2 and 4 kPa (Fig. 4A).
For inhalers that deliver more or less the same amount of
FPF over the entire range of attainable pressure drops
(>2 kPa), higher pressure drops (corresponding with higher
flow rates) are not desirable, because this is at the cost of
total (in particular central and peripheral) lung deposition
due to increased losses in the oropharynx at the higher flow
rates. DPIs with IFR-independent FPF generation are
frequently low-resistance devices, which facilitate the gen-
eration of higher IFRs. For instance, the increase in flow rate
between 2 and 4 kPa through a high-resistance inhaler like
the HandiHaler is only from 28 to 39 L/min versus
57e106 L/min for the low-resistance Aerolizer. In contrast,
DPIs delivering a higher FPF with increasing IFR are
frequently high-resistance devices. Fig. 4B compares the
flow rates at which FPF <5 mm reaches the value of 25% of
label claim for the inhalers presented in Fig. 4A. The dif-
ference is between 36.4 L/min for the medium/high-resis-
tance Symbicort Turbuhaler and 82.2 L/min for the low-
resistance Cyclohaler. On the basis of the impaction
parameter (based on flow rate) as predictor for inertial
impaction, this might give a 2.25 times higher chance of
oropharyngeal impaction for the same particle size for the
low-resistance device. For the Diskus, Clickhaler and
Elpenhaler FPF values of 25% of label claim were not ob-
tained at any flow rate with the devices used to produce
Fig. 4A. Attaining a pressure drop of 2e4 kPa e which is
sufficient to operate most inhalers successfully and results in
clinically effective drug delivery e is easier when using a
high-resistance inhaler than when using a low-resistance
device, independent of the type and severity of the dis-
ease [13,31,50]. Even during exacerbations of asthma and
COPD, patients are able to achieve the required pressure
drop and the performance of an inhaler with a higher resis-
tance is less influenced by the underlying degree of bron-
choconstriction than with a low-resistance inhaler [31]. Also,
young children and adult patients with severely impaired
lung function generate sufficiently high pressure drops to
enable them to use IFR-dependent higher resistance inhalers
such as the Turbuhaler and Novolizer effectively [13,31].The ideal dry powder inhaler?
Determining the best inhaler is dependent on the circum-
stances and characteristics of each patient, so may vary indifferent clinical settings. However, based on the consid-
erations discussed above and balancing the requirements of
a broad range of patients, the ideal DPI device would have
the following characteristics: a high and consistent IFR-
dependent FPF (contributing to consistent central and pe-
ripheral lung deposition regardless of IFR) and a medium to
high internal resistance to limit the IFR and minimise loss of
the FPF dose in the oropharynx. In addition, the inhaler
should be easy for patients to learn and maintain correct
usage and small enough to be convenient to carry around or
store, to minimise incorrect use and maximise adherence to
the therapy [16]. Table 1 shows how some of the widely
used inhalers measure up to these requirements. Originator
devices like the Turbuhaler and Novolizer deliver a high
FPF (1e3 mm) to the central and peripheral airways, where
the medication being delivered (either bronchodilator or
anti-inflammatory ICS) is generally most needed, up to 40%
or more of the label claim at the flow rate corresponding
with 6 kPa [29,30,33,43e46]. In contrast, some generic in-
halers like the Elpenhaler deliver more or less the same
low FPF of <20% at all flow rates.Conclusions
There are a growing number of dry powder inhalers avail-
able and these differ greatly in their design, technical
characteristics and other individual features. Some inhalers
have characteristics that mean they are likely to work for a
variety of patients, which may provide a certain level of
convenience for physicians. However, there are many fac-
tors to consider when selecting the optimal inhaler for
patients with asthma or COPD. Apart from the type of drug
inside the inhaler, the level of clinical evidence for its ef-
ficacy and safety, doctor and patient preferences, the
technical characteristics of the different inhalers and the
delivery and deposition of the fine particle dose to the
lungs may be important additional considerations to help
the physician to select the most appropriate device for the
individual patient to optimise their treatment.Conflict of interest statements
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